In the quiet hum of an ultrasound lab, a team of researchers is betting on the power of sound to make cancer drugs more precise. The goal is not just to deliver a therapy, but to deliver it exactly where it is needed, using a trigger doctors already have in their hands. For patients facing aggressive cancers, the promise is a treatment that works better and feels less toxic, a fundamental shift from systemic bombardment to targeted instruction.
That is the bet being placed by MusiQ Bio, a Dallas-based biotech spun out of UT Southwestern Medical Center. The company’s core technology, developed during the COVID lockdowns, engineers microscopic gas-filled bubbles to carry drug payloads through the bloodstream. When these microbubbles reach their target,guided by antibodies to specific cells,a focused pulse of ultrasound makes them oscillate and collapse, releasing their cargo directly into the tissue. The approach, which the company calls Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (MUSIC), recently secured a $2.59 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance toward human trials [UT Southwestern, September 2026].
The Wedge of Sound and Specificity
The technical premise rests on a clever repurposing of existing medical tools. Microbubbles, slightly smaller than a red blood cell, have been used safely for decades as contrast agents to improve ultrasound imaging. MusiQ Bio’s innovation is to turn them into programmable delivery vehicles. By attaching both targeting molecules and therapeutic agents to the bubble’s shell, the company aims to achieve a level of spatial precision that intravenous infusion cannot match [IEEE Pulse, retrieved 2026].
Early academic work from the founding lab focused on delivering a specific immune-stimulating molecule called cGAMP to antigen-presenting cells within tumors. In mouse models of triple-negative breast cancer, a particularly challenging disease, the MUSIC strategy reportedly reduced tumor growth and eliminated tumors in 60% of the animals, while also preventing regrowth [UT Southwestern, September 2026]. The hope is that by activating the immune system precisely within the tumor microenvironment,a concept known as in situ vaccination,the therapy could enhance the effects of existing immunotherapies with fewer off-target side effects.
An Academic Trinity at the Helm
The company’s trajectory is deeply rooted in the academic collaboration that created it. The founding team represents a classic trinity of biotech translation: deep science, clinical translation, and commercial execution.
| Role | Founder | Key Background |
|---|---|---|
| Chief Scientific Officer | Sina Khorsandi, Ph.D. | Developed the MUSIC platform as a postdoctoral researcher in the Lux Lab at UT Southwestern [UT Southwestern, September 2026]. |
| Scientific Advisor & Co-founder | Jacques Lux, Ph.D. | Associate Professor of Radiology and Biomedical Engineering at UTSW; directs the Translational Research in UltraSound Theranostics (TRUST) program [LinkedIn, retrieved 2026]. |
| Chief Executive Officer | Manwal Harb, Ph.D. | Rice University bioengineering alumnus who moved from his dissertation defense to co-founding the company [Rice University, September 2026]. |
Khorsandi initiated the project in 2020, building on Lux’s lab work with sound-responsive materials. Harb, the CEO, brings the operational focus to steer the academic insight toward the clinic. The CPRIT grant, categorized as a seed grant for product development, is a critical non-dilutive capital infusion that validates the project within Texas’s robust cancer research ecosystem and funds the necessary preclinical work [MusiQ Bio Receives $2.6M CPRIT SEED Grant, retrieved 2026].
Navigating the Path to the Clinic
The funding provides a runway, but the path ahead is defined by the rigorous milestones of biotech development. The company’s stated goal is to reach first-in-human clinical trials within five years [UT Southwestern, September 2026]. Getting there requires navigating a series of complex, interdependent challenges.
- Manufacturing and Scalability. Engineering consistent, stable microbubbles at a quality suitable for human use is a significant biochemical challenge. The process must be reproducible and compliant with Good Manufacturing Practices (GMP), a leap from lab-scale production.
- Delivery Optimization. The company is already iterating on its platform, developing a second system called SONATA that shrinks the bubbles to one-tenth their original size to improve tumor penetration [UT Southwestern, September 2026]. Each modification requires new validation in animal models.
- Regulatory Strategy. MusiQ Bio will need to define a clear regulatory pathway with the FDA, likely pursuing an Investigational New Drug (IND) application. The safety profile of the microbubble component, based on its long history as a contrast agent, could be a relative advantage in early discussions.
The competitive landscape for targeted drug delivery is crowded with modalities like lipid nanoparticles, antibody-drug conjugates, and other nanoparticle systems. MusiQ Bio’s differentiation hinges on the unique, externally controllable trigger of ultrasound, which could allow for temporal precision,treating only when the bubble has reached the target,in addition to spatial targeting.
The Patient Population in Focus
The initial research targets triple-negative breast cancer, a disease state known for its aggressiveness and limited treatment options compared to hormone receptor-positive cancers. The standard of care today often involves a combination of chemotherapy, surgery, and radiation, with immunotherapy like checkpoint inhibitors playing an increasing but still limited role. These systemic treatments can be effective but are frequently accompanied by significant side effects that diminish quality of life, a trade-off that is especially acute in aggressive cancers.
For this patient population, the clinical promise of a platform like MUSIC is twofold. First, it aims to enhance the efficacy of immunotherapies by directly stimulating an immune response within the tumor. Second, and just as critical from a patient perspective, it seeks to confine the powerful effects of the drug to the disease site, potentially reducing the debilitating systemic side effects that accompany traditional chemotherapy or broad-acting immunotherapies. The company’s longer-term vision includes exploring the platform’s utility in other solid tumors, a common expansion path for a targeted delivery technology [IEEE Pulse, retrieved 2026].
The next twelve months for MusiQ Bio will be measured in data points, not headlines. Progress will be defined by iterative experiments, scaling the bubble manufacturing process, and generating the robust preclinical data package needed to attract the next round of investment,likely a traditional venture round,to fund the final push toward the clinic. The CPRIT grant has given them the score, but the hard work of orchestration lies ahead.
Sources
- [UT Southwestern, September 2026] UTSW spinoff receives $2.6 million CPRIT grant to develop novel cancer immunotherapy | https://www.utsouthwestern.edu/newsroom/articles/year-2026/sept-cprit-grant-cancer-immunotherapy.html
- [Rice University, September 2026] Rice alumnus’ startup receives $2.6 million CPRIT grant to advance immunotherapy for breast cancer | https://engineering.rice.edu/news/rice-alumnus-startup-receives-26-million-cprit-grant-advance-immunotherapy-breast-cancer
- [IEEE Pulse, retrieved 2026] Ultrasound and Microbubbles Combine for Drug Delivery, Detecting Biomarkers | https://www.embs.org/pulse/articles/ultrasound-and-microbubbles-combine-for-drug-delivery-detecting-biomarkers/
- [LinkedIn, retrieved 2026] MusiQ Bio Receives $2.6M CPRIT SEED Grant | https://www.linkedin.com/posts/manwalharb_cancer-prevention-research-institute-texas-activity-7496216891166781440-6Nxh
- [LinkedIn, retrieved 2026] Jacques Lux - Director of the Translational Research in UltraSound Theranostics (TRUST) Research Program - UT Southwestern Medical Center | https://www.linkedin.com/in/jacqueslux/